Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). All seven directors intend to resign upon merger closing, transitioning Catalyst to Angelini Pharma ownership.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- All seven directors intend to resign upon merger closing, transitioning Catalyst to Angelini Pharma ownership
- Resignations include Patrick J. McEnany, Richard J. Daly, and five additional directors
- Departures cover the board and applicable committees, consistent with anticipated post-merger governance
- No resignations stem from disagreements over operations, policies, or practices
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Merger with Angelini Pharma approved: 97,340,180 votes for versus 1,143,815 against
- 80.6% of outstanding shares participated, satisfying the stockholder-approval closing condition
- Compensation vote rejected 67,486,884 to 30,504,686, but advisory result does not block closing
- Adjournment unnecessary because sufficient votes supported the merger
- Closing remains subject to other merger-agreement conditions, regulatory approvals, and potential termination risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.